X

Trial Profile

A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Safusidenib (Primary)
Indications Glioma
Focus Adverse reactions; Therapeutic Use
Sponsors Daiichi Sankyo Company

Most Recent Events

10 Apr 2024 According to a Nuvation Bio media release, AnHeart Therapeutics has been acquired by Nuvation Bio and AnHeart is now a wholly-owned subsidiary of Nuvation Bio.
05 Dec 2023 Timeline for primary end-points decreased from 6 years to 24 months.
04 Aug 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Sep 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com